Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.

被引：0
|
作者：
Garber, JE
Halabi, S
Kaplan, E
Edge, S
Dressler, L
Paskett, E
Berliner, N
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Duke Univ, Durham, NC 27706 USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Yale Univ, Sch Med, New Haven, CT 06520 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：6S / 6S
页数：1
相关论文
共 50 条
  • [11] Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease
    Herrington, DM
    Vittinghoff, E
    Howard, TD
    Major, DA
    Owen, J
    Reboussin, DM
    Bowden, D
    Bittner, V
    Simon, JA
    Grady, D
    Hulley, SB
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (06) : 1012 - 1017
  • [12] The association between Factor V Leiden and thromboembolic events in autopsy patients.
    Sanders, ME
    Soltys, S
    Litzky, LA
    Leonard, DGB
    LABORATORY INVESTIGATION, 1998, 78 (01) : 6A - 6A
  • [13] Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
    Pritchard, KI
    Paterson, AHG
    Paul, NA
    Zee, B
    Fine, S
    Pater, J
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2731 - 2737
  • [14] Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium
    Mehmet Yilmazer
    Gulay Kurtay
    Murat Sonmezer
    Nejat Akar
    Archives of Gynecology and Obstetrics, 2003, 268 (4) : 304 - 308
  • [15] Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial
    Decensi, A
    Maisonneuve, P
    Rotmensz, N
    Bettega, D
    Costa, A
    Sacchini, V
    Salvioni, A
    Travaglini, R
    Oliviero, P
    D'Aiuto, G
    Gulisano, M
    Gucciardo, G
    del Turco, MR
    Pizzichetta, MA
    Conforti, S
    Bonanni, B
    Boyle, P
    Veronesi, U
    CIRCULATION, 2005, 111 (05) : 650 - 656
  • [16] Factor V Leiden (FVL), prothrombin, MTHFR and PAI-1 polymorphisms and cancer risk in women; the Jerusalem perinatal study (JPS)
    Tiram, E.
    Friedlander, Y.
    Kadouri, L.
    Manor, O.
    Isacson, R.
    Yanetz, R.
    Deutsch, L.
    Harlap, S.
    Pattiel, O.
    THROMBOSIS RESEARCH, 2007, 120 : S176 - S177
  • [17] Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.
    Liu, M. C.
    Dixon, J. M.
    Xuan, J. J.
    Riggins, R. B.
    Chen, L.
    Wang, C.
    Cho, Y.
    Zhu, Y.
    Jin, L.
    Zwart, A.
    Wang, M.
    Klimach, U. M.
    Wang, Y. J.
    Renshaw, L.
    Larionov, A.
    Miller, W. R.
    Clarke, R.
    CANCER RESEARCH, 2011, 71
  • [18] Relationship between Factor V Leiden mutation and venous thromboembolism in patients with breast cancer treated with tamoxifen
    Onitilo, Adedayo A.
    Doi, Suhail A. R.
    Engel, Jessica M.
    Glurich, Ingrid
    Berg, Richard
    THROMBOSIS RESEARCH, 2013, 131 (06) : 567 - 568
  • [19] Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen.
    Loi, SM
    Desmedt, C
    Haibe-Kains, B
    Lallemand, F
    Gillett, C
    Tutt, A
    Ryder, K
    Ellis, P
    Harris, P
    Smeds, J
    Bergh, J
    Cardoso, F
    Piccart, MJ
    Sotiriou, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S129 - S130
  • [20] Operabile breast cancer in postmenopausal women on adjuvant antiestrogen tamoxifen
    Veselinovic, S
    Filipovic, S
    Projevic, M
    Stojanovic, D
    Buric, M
    BALKAN CONGRESS OF ONCOLOGY, 1996, : 447 - 450
12345